[Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit].
BACKGROUND
Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIla (rFVlla) constitutes a new therapeutic alternative.


OBJECTIVE
Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVlla.


METHODS
Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001.


RESULTS
Among patients treated with rFVlla, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001).


CONCLUSIONS
rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.
Carrillo-Esper
Raúl
R
Academia Nacional de Medicina, Academia Mexicana de Cirugía, México D. F., México. sencocapcmamail@medinet.net.mx
Sánchez-Zúñiga
Martín de Jesús
Mde J
Elizondo-Argueta
Sandra
S
Visoso-Palacios
Porfirio
P
Carrillo-Córdova
Jorge Raúl
JR
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D016913:Blood Component Transfusion; D016638:Critical Illness; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa